Elutia Inc. (ELUT)

Market Cap	149.18M
Revenue (ttm)	24.78M
Net Income (ttm)	-54.20M
Shares Out	34.06M
EPS (ttm)	-1.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,351
Open	4.270
Previous Close	4.210
Day's Range	4.010 - 4.420
52-Week Range	1.630 - 5.240
Beta	0.76
Analysts	Strong Buy
Price Target	10.00 (+128.31%)
Earnings Date	Nov 14, 2024

About ELUT

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women’s Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 8, 2020
• Employees: 54
• Stock Exchange: NASDAQ
• Ticker Symbol: ELUT
• Website: https://elutia.com

Financial Performance

In 2023, Elutia's revenue was $24.75 million, an increase of 3.76% compared to the previous year's $23.85 million. Losses were -$37.66 million, 14.5% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for ELUT stock is "Strong Buy." The 12-month stock price forecast is $10.0, which is an increase of 128.31% from the latest price.

Price Target

$10.0

(128.31% upside)

Analyst Consensus: Strong Buy